Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $126
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch has reaffirmed a Buy rating on Abbott Laboratories (NYSE:ABT) and increased the price target from $123 to $126, indicating a positive outlook on the company's stock.
January 25, 2024 | 4:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Joanne Wuensch maintains a Buy rating on Abbott Laboratories and raises the price target from $123 to $126, suggesting confidence in the company's future performance.
The increase in price target by Citigroup reflects a positive assessment of Abbott Laboratories' prospects, which is likely to be viewed favorably by investors. This endorsement from a major financial institution can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100